Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofox-P is a fixed-dose combination analgesic and antipyretic medication developed by Aarise Pharmaceuticals. It contains diclofenac potassium, a non-steroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen). Diclofenac potassium provides rapid-onset relief by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of prostaglandins that mediate pain and inflammation. Paracetamol acts primarily within the central nervous system to elevate the pain threshold and reduce fever, potentially through the inhibition of a central COX variant (often referred to as COX-3). This combination is typically indicated for the management of acute pain and inflammation associated with musculoskeletal disorders, post-operative recovery, and various arthritic conditions such as rheumatoid arthritis and osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac potassium + paracetamol.